Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06216197
Other study ID # 0395/2023
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 3, 2021
Est. completion date December 4, 2022

Study information

Verified date January 2024
Source Zulekha Hospitals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dexmedetomidine is recommended over fentanyl as adjunctive medication to bupivacaine for saddle block spinal anesthesia in anal surgeries and procedures.


Description:

Objectives: A saddle spinal block is a viable choice for anal surgeries. This technique effectively maintains balanced hemodynamics, and fast recovery, and prevents irrelevant motor blocks in both limbs. Methods: Fifty-eight adult patients were categorized into two groups. Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg). The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml). Continuous monitoring of HR and SpO2 was conducted. Evaluation of sensory blockage and the motor block was done utilizing the Bromage scale. Following surgery, assessments were conducted. Pain in the ward and PACU was determined utilizing the visual analog scale (VAS).


Recruitment information / eligibility

Status Completed
Enrollment 58
Est. completion date December 4, 2022
Est. primary completion date December 4, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria: - both sexes - aged between 20 and 60 - classified as II & ASA-I - scheduled for elective anal surgeries Exclusion Criteria: - subjects who refused to participate - uncontrolled hypertension - BMI > 30 kg/m2 - heart failure (class IV or III) based on the New York Heart Association (NYHA) - uncorrected coagulopathy - any study's drug allergy - drug abuse - neuropathy - any spinal anesthesia contraindication (such as infection or a pelvic fracture)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FENT group
Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 µg).
DEX group
The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 µg; 0.5 ml).

Locations

Country Name City State
Egypt Al-Azhar faculty of medicine Cairo

Sponsors (1)

Lead Sponsor Collaborator
Zulekha Hospitals

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary the duration until the first call for analgesia the duration until the first call for analgesia 20 months
Secondary the duration from spinal injection until reaching the maximal sensory level the duration from spinal injection until reaching the maximal sensory level 20 months
Secondary the duration needed for sensory regression to occur over two spinal segments from the maximal sensory level the duration needed for sensory regression to occur over two spinal segments from the maximal sensory level 20 months
Secondary the time required for sensory regression until reaching the S1 level (from the maximal sensory level) the time required for sensory regression until reaching the S1 level (from the maximal sensory level) 20 months
Secondary the duration from injection to achieving Bromage 0, the total tramadol consumption (until the first 24 hours) the duration from injection to achieving Bromage 0, the total tramadol consumption (until the first 24 hours) 20 months
Secondary side effects occurrences side effects occurrences 20 months
See also
  Status Clinical Trial Phase
Recruiting NCT06005480 - Understanding Rebound Pain After Regional Anesthesia Resolution in Healthy Volunteers Phase 1
Completed NCT04565093 - Efficacy of iPACK After Unilateral TKA N/A
Recruiting NCT06074471 - Motor Sparing Supraclavicular Block N/A
Completed NCT03740815 - Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection N/A
Completed NCT02524652 - Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction Phase 4
Completed NCT03913429 - Ultrasound-guided Bilateral Suprazygomatic Maxillary Nerve Block and Bimaxillary Osteotomy N/A
Completed NCT05012332 - Local Anesthesia Spread After an Erector Spinae Plane Block. N/A
Withdrawn NCT04015284 - Intraoperative Pain and Quality of Surgical Block During Shoulder Surgery Assessed by NOL Index N/A
Recruiting NCT05432934 - Transversus Abdominis Plane Blocks With and Without Dexamethasone Phase 1/Phase 2
Recruiting NCT05512897 - Does ESP Block Reduce Pain and Opiates Consumption After Surgery N/A
Completed NCT04085263 - Rhomboid Intercostal and Subserratus Plane Block N/A
Not yet recruiting NCT04001387 - Feasibility of Real-time Ultrasound-guided Spinal Anesthesia Using Dynamic Needle Tip Positioning
Active, not recruiting NCT05478629 - Safety of Regional Anesthesia in Ukraine: the Survey
Terminated NCT03296033 - Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin Phase 4
Withdrawn NCT02603900 - Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty Phase 4
Completed NCT03666845 - Plasma Ropivacaine Concentrations After Sciatic Nerve Block in Patients With Chronic Kidney Disease
Completed NCT03394807 - LaGRA Trial in Laparoscopic Cholecystectomy Phase 4
Completed NCT05558449 - Impact of Virtual Reality Hypno-sedation on Functional Recovery and Anxiety in Foot Surgery With Regional Anesthesia Phase 4
Completed NCT02433561 - Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block Phase 4
Recruiting NCT06147401 - Comparison of PENG Associated With LFCN Block Versus FICB for Multimodal Analgesic Management in THA N/A